Mar 4, 2025
Olivier Visa, President and CEO of Evergen specializes in developing and manufacturing biomaterials for use in regenerative medicine. These customized biomaterial solutions use xenografts, allografts, and emerging technologies inside and outside the body with applications in wound healing, cardiac, dental, breast,...
Mar 4, 2025
Olivier Visa, President and CEO of Evergen specializes in developing and manufacturing biomaterials for use in regenerative medicine. These customized biomaterial solutions use xenografts, allografts, and emerging technologies inside and outside the body with applications in wound healing, cardiac, dental, breast,...
Feb 5, 2024
Chris Paradise, VP of Research and Development at Rion, is taking an acellular approach to developing next-generation regenerative medicines to treat degenerative diseases. The proprietary Rion system PEP, purified exosome product, uses extracellular vesicles or exosomes isolated from human blood platelets to send...
Feb 5, 2024
Chris Paradise, VP of Research and Development at Rion, is taking an acellular approach to developing next-generation regenerative medicines to treat degenerative diseases. The proprietary Rion system PEP, purified exosome product, uses extracellular vesicles or exosomes isolated from human blood platelets to send...
Sep 29, 2022
Jason Matuszewski, Chief Executive Officer and Chairman of the Board, and Andrew Van Vurst, Chief Operating Officer of BioStem Technologies have a vision to change the paradigm on the use of perinatal tissue for advanced wound care. Their initial target is complex wounds in the lower extremity region, specifically...